AQW051 + AQW051 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyskinesias

Conditions

Dyskinesias, Drug-induced

Trial Timeline

Sep 15, 2011 → Feb 21, 2013

NCT ID

NCT01474421

About AQW051 + AQW051 + Placebo

AQW051 + AQW051 + Placebo is a phase 2 stage product being developed by Novartis for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT01474421. Target conditions include Dyskinesias, Drug-induced.

What happened to similar drugs?

0 of 1 similar drugs in Dyskinesias were approved

Approved (0) Terminated (0) Active (1)

🔄Levodopa-carbidopa intestinal gelAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01474421	Phase 2	Completed	Sep 15, 2011	Feb 21, 2013	Dyskinesias

Competing Products

4 competing products in Dyskinesias

See all competitors

Product	Company	Stage	Hype Score
Levodopa-carbidopa intestinal gel	AbbVie	Phase 3	40
AFQ056	Novartis	Phase 2	35
AFQ056 + Placebo	Novartis	Phase 2	35
AFQ056 + Placebo	Novartis	Phase 2	35